Two more biotechs price IPOs, bring­ing to­tal raise to record heights

Atea Phar­ma­ceu­ti­cals and SQZ Biotech­nolo­gies have priced their pub­lic de­buts, adding to this year’s record biotech IPO raise — a pot spilling over $13 bil­lion that dwarfs the to­tal rais­es of the last four years.

Last Fri­day, Nas­daq head of health­care list­ings Jor­dan Saxe count­ed 72 biotech and bio­phar­ma IPOs this year, to­geth­er rais­ing $13.2 bil­lion. He pegged a “fair es­ti­mate” of 75 de­buts and just un­der $14 bil­lion in pro­ceeds to round out the year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.